RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA
Trial details
- Registry ID
- NCT06146101
- Phase
- Phase 2, Phase 3
The FDA approved Acetazolamide (Phase 3 Comparator - Reference Listed Drug/Acetazolamide) on 27 Jul 1953.
Drug identity checked against registry records
Also recorded as Phase 3 Comparator - Reference Listed Drug/Acetazolamide
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSANCT06146101 | Incannex Healthcare Ltd | Phase 2, Phase 3 | Completed | 2025-05-20Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1953-07-27Day | Acetazolamide | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA008943", "applicant_as_listed_by_fda": "TEVA BRANDED PHARM", "brand_names": ["DIAMOX"], "active_ingredients": ["ACETAZOLAMIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19530727", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |